Why an M1 Antagonist Could Be a More Selective Model for Memory Impairment than Scopolamine

Research output: Contribution to journalArticleAcademicpeer-review

162 Downloads (Pure)
Original languageEnglish
Article number167
Number of pages4
JournalFrontiers in Neurology
Volume7
DOIs
Publication statusPublished - 30 Sep 2016

Keywords

  • actelylcholine
  • Alzheimer
  • cognition enhancer
  • memory
  • deficit model
  • MUSCARINIC ACETYLCHOLINE-RECEPTOR
  • PSYCHOMOTOR PERFORMANCE
  • COGNITIVE PERFORMANCE
  • ALZHEIMERS-DISEASE
  • M-1
  • LORAZEPAM
  • XANOMELINE
  • MODULATION
  • AGONIST
  • DRUGS

Cite this